Germline STK11 mutations are associated with lung adenocarcinoma, cervical cancer, and hepatocellular carcinoma (99,100). Additionally, inactivation of STK11 through homozygous deletion has also been observed in lung (101), specifically non-small cell lung carcinoma (102), breast (103) and pancreatic (104) cancers. Here, STK11 is linked to non-small cell lung carcinoma.